GEN Exclusives

More »

GEN News Highlights

More »
Nov 18, 2011

Shire, Shionogi Ink Co-Development Agreement for ADHD Drugs in Japan

  • Intent on tapping one of the world’s fastest-growing markets for ADHD treatments, Shire and Japan’s Shionogi & Co. agreed to co-develop and co-commercialize some of Shire’s medicines for the psychiatric behavioral disorder. Upon approval of medicines for Japan, Shionogi will pay a one-time fee and share costs with Shire.

     

    Shire’s drugs for ADHD include Adderall XR, Intuniv, Vyvanse. All three recorded double-digit year-over-year sales gains during the third quarter, with the first two increasing by 50%, and Vyvanse, by 32%. Shionogi develops medicines for the central nervous system, among other therapeutic areas.

     

    The agreement comes nearly three years after Shire opened a representative office in Japan, with the goal of stepping up commercialization of its pipeline products in Japan, the world’s second largest biopharmaceutical market.

     


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?